Rebalix
Logo InvescoInvesco · sheet of 5 September 2026
ETF sheet · official issuer and register data

Invesco S&P World Health Care ESG UCITS ETF Acc

WDHE · IE000L4EH2K5 · class Acc · USD · domicile Ireland
Equity · Global · Health care · Sustainable / ESGSFDR art. 8
Index tracked: S&P World ESG Enhanced Health Care Index
TER
0.18%+ trans. 0.02%
Fund size
10 m EUR
Tracking difference
not computable
🇮🇹 tax rate
26.00%white list 0.00%
Replication
Physical
Income
Accumulating
Launch 12 Apr 2023 · costs from the KID as of 14 Aug 2026 · 76 securities held · 9 venues (ESMA register)

The fund’s objective — in the issuer’s words

From the Key Information Document (KID) · 14 Aug 2026
Investment objective: The objective of the Fund is to achieve the net total return performance of the S&P World ESG Enhanced Health Care Index (the "Index"), less fees, expenses and transaction costs. Investment approach: The Fund is a passively managed ETF. To achieve the investment objective, the Fund will, as far as possible and practicable, hold all the securities in the Index in their respective weightings. The Fund may use derivative instruments for the purposes of managing risk, reducing costs, generating additional capital or income. The Fund may…

Performance since series start (in euro) — base 100

12 Apr 202311 Aug 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
20242025202612293120
High 122 (2 Sept 2024) · low 93 (13 Jul 2023) · last 120. Past performance is not indicative of future results.

Returns in euro

1 year+25.5%
3 years+20.8%
5 yearsseries too young
10 yearsseries too young
Since series start+20.2%

Risk · 1 / 3 / 5 years

Volatility (ann.)16.26%13.87%
Max drawdown−12.83%−19.64%
Sharpe1.090.49
Sortino1.860.71
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · WDHE · IE000L4EH2K51
RebalixWDHE · IE000L4EH2K5 · sheet of 5 September 2026

Tracking difference — year by year

Fund minus index, complete calendar years · from issuer-declared series
YearFundIndexTD
2025+15.45%+15.40%+0.04%
2024+1.65%+1.60%+0.05%

Holdings

Portfolio as declared by the issuer · 1 Sept 2026 · 76 securities · top-10 weight = 63.6%
Top holdingsWeight
ELI LILLY & CO NPV15.8%
ABBVIE INC USD0.0111.4%
MERCK & CO. INC. USD0.57.3%
NOVARTIS AG-REG CHF0.54.8%
ASTRAZENECA PLC USD0.254.5%
GILEAD SCIENCES INC USD0.0014.5%
ROCHE HOLDINGS AG CHF NPV4.2%
AMGEN INC USD0.00014.1%
ABBOTT LABORATORIES NPV3.8%
THERMO FISHER SCIENTIFIC INC USD13.3%
Countries (% of fund)
United States83.1%United Kingdom5.5%Japan4.2%Other1.6%Germany1.2%
Sectors (% of fund)
Health Care100.0%

Listing venues

ESMA register (FIRDS) and official exchange lists
WDHE · Borsa Italiana (ETFplus)
WH2E · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 9 unmapped venues (MTF, RFQ, professional)

Official documents

Clickable links in the PDF
KID · www.invesco.com/content/dam/invesco/emea/en/product-documents/etf/shar
Factsheet · www.invesco.com/content/dam/invesco/emea/en/product-documents/etf/shar
Prospectus · www.invesco.com/content/dam/invesco/emea/en/product-documents/etf/umbr
The live sheet, always up to date
rebalix.com/en/etf/IE000L4EH2K5
Series, distributions, holdings and documents refresh daily.
Sheet produced on 5 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.

Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.

Rebalix · WDHE · IE000L4EH2K52